



## PRESS RELEASE

### Trillium Adds Major Cytokine Receptor Antagonist Program

**Toronto, Canada – June 2<sup>nd</sup>, 2004** - Trillium Therapeutics Inc. (TTI) today announced that it has licensed exclusive worldwide rights to a series of highly potent pro-inflammatory cytokine receptor antagonists. The technology was developed at St. Justine Hospital and the University of Montreal in the laboratories of Drs. Sylvain Chemtob and William Lubell.

“The combination of potent therapeutic candidates with IC50 values in the picomolar range, a validated immunotherapy target, impressive proof-of-principle *in vivo* data, as well as innovative and proprietary science, made this an ideal in-licensing opportunity for TTI”, explains Dr. Bob Uger, Trillium’s Vice President, Research & Development. “This technology is a true example of what can be accomplished with a rational drug design approach, and we welcome the opportunity to oversee and facilitate its transition from a research project into a development program.”

In keeping with the overall strategy for all of its projects, TTI will continue to work closely with the inventors, and their respective academic institutions, and will provide funding to support various research activities. The company will also expand its internal resources and broaden its external network of collaborators, to accommodate this new technology.

“TTI continues to add value and reduce risk through the creation of a solid R&D base with multiple product opportunities. The addition of this promising technology allows us to diversify our therapeutic approaches and targets, while still keeping our focus on immune-mediated disorders”, adds Trillium CEO Dr. Niclas Stiernholm.

Trillium Therapeutics Inc. is a privately held Research and Development company that specializes in the development of innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses. These include autoimmune and inflammatory disorders, graft rejection, cancer and viral hepatitis. The Company identifies therapeutic candidates with promising preclinical profiles and advances these into clinical testing, with the primary objective of demonstrating safety and efficacy in humans. TTI currently has three development programs, one based on the CD200 immunoregulatory protein

and its receptor, a second targeting the novel pro-thrombinase Fgl2, and a third that focuses on cytokine receptor antagonists. TTI has a broad network of external R&D collaborations, including several with major pharmaceutical and biotechnology companies.

For further information, please contact:

Niclas Stiernholm, Ph.D.  
Chief Executive Officer  
Trillium Therapeutics Inc.  
96 Skyway Avenue  
Toronto, Ontario, M9W 4Y9  
Canada

Tel: (416) 595-0627  
Fax: (416) 595-5835  
[niclas@trilliumtherapeutics.com](mailto:niclas@trilliumtherapeutics.com)  
[www.trilliumtherapeutics.com](http://www.trilliumtherapeutics.com)